title: Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes.
abstract: Glyxambi®(empagliflozin/linagliptin) is a fixed-dose, once-daily tablet combining a sodium glucose co-transporter-2 (SGLT2) inhibitor with a dipeptidyl peptidase-4 (DPP-4) inhibitor. Glyxambi®is served as an adjuvant to diet and exercise to improve glycemic control in adults with type 2 diabetes when both empagliflozin and linagliptin are appropriate treatments. Glyxambi®combines 10mg or 25mg empagliflozin with 5mg linagliptin, with different, complementary mechanisms of action to improve glycemic control in patients with type 2 diabetes. Empagliflozin removes glucose through the urine by blocking blood glucose re-absorption in the kidney, and linagliptin exerts glucose-lowering activity by increasing hormones that stimulate the pancreas to produce more insulin and decreasing the levels of glucagon in the circulation. In addition, this combination therapy modestly reduces body weight and blood pressure without significant safety issues.
authors.affiliation: Department of endocrinology, Ningbo University Affiliated Yuyao Yangming Hospital, 315400 Yuyao, China. Electronic address: tanxueying@163.com.
authors.forename: Xueying
authors.initials: X
authors.lastname: Tan
authors.affiliation: College of Pharmaceutical Science, Zhejiang University, 866 Yuhangtang Road, 310058 Hangzhou, China. Electronic address: hujiaabo@163.com.
authors.forename: Jingbo
authors.initials: J
authors.lastname: Hu
mesh_terms: D001559:Benzhydryl Compounds / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D004359:Drug Therapy, Combination; D005960:Glucosides / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D000069476:Linagliptin / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics
chemical_list: D001559:Benzhydryl Compounds; D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D005960:Glucosides; D007004:Hypoglycemic Agents; D000069476:Linagliptin; C570240:empagliflozin
keywords: Diabète de type 2; Empagliflozin; Empagliflozine; Glyxambi(®); Linagliptin; Linagliptine; Type 2 diabetes